Development of bivalent rgp120 vaccines to prevent HIV type 1 infection

AIDS Research and Human Retroviruses

Volumn 14, Issue SUPPL. 3, 1998, Pages

  Berman, P W ^a  

^a VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RABBIT; REVIEW; VACCINE PRODUCTION; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; EPIDEMIOLOGY, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RABBITS; T-LYMPHOCYTES; VARIATION (GENETICS);

EID: 0031764239     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)